Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and PD-1 inhibitor in second-line HCC
NCT05048017Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2021
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of regorafenib, camrelizumab, toripalimab and pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Peking Union Medical College Hospital. Started Oct 2021; status: recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05048017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048017.